Literature DB >> 1639943

Normal calcitonin stimulation of serum calcitriol in patients with X-linked hypophosphatemic rickets.

M J Econs1, B Lobaugh, M K Drezner.   

Abstract

Patients with X-linked hypophosphatemic rickets (XLH) have normal or low calcitriol concentrations despite manifesting hypophosphatemia, a known stimulus of 25-hydroxyvitamin D-1 alpha-hydroxylase activity. In accord, administration of pharmacological doses of PTH results in a markedly blunted stimulation of calcitriol levels. In the murine homolog of the human disorder, the Hyp mouse, regulation of 25-hydroxyvitamin D-1 alpha-hydroxylase activity is defective in response to hypophosphatemia and PTH administration, but not in response to calcitonin administration. In the current study we administered calcitonin to controls and patients with XLH to test the hypothesis that calcitonin-stimulatable 25-hydroxyvitamin D-1 alpha-hydroxylase activity is normal in patients with XLH. We found that calcitriol concentrations increased in both groups to a similar degree (78.5 +/- 20.9 pmol/L in patients and 49.9 +/- 19.7 pmol/L in controls) and with a similar time course. Our results indicate that the complex and incomplete defect in the regulation of 25-hydroxyvitamin D-1 alpha-hydroxylase observed in Hyp mice also exists in humans.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639943     DOI: 10.1210/jcem.75.2.1639943

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors:  Emily G Farrow; Erik A Imel; Kenneth E White
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

Review 2.  The changing face of hypophosphatemic disorders in the FGF-23 era.

Authors:  Janet Y Lee; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2013-06

3.  Calcitonin administration in X-linked hypophosphatemia.

Authors:  Eva S Liu; Thomas O Carpenter; Caren M Gundberg; Christine A Simpson; Karl L Insogna
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

Review 4.  Pharmacological management of X-linked hypophosphataemia.

Authors:  Erik A Imel; Kenneth E White
Journal:  Br J Clin Pharmacol       Date:  2018-10-29       Impact factor: 4.335

5.  Circadian rhythm and cartilage extracellular matrix genes in osseointegration: a genome-wide screening of implant failure by vitamin D deficiency.

Authors:  Cristiane Machado Mengatto; Federico Mussano; Yoshitomo Honda; Christopher S Colwell; Ichiro Nishimura
Journal:  PLoS One       Date:  2011-01-11       Impact factor: 3.240

Review 6.  FGF23, Hypophosphatemia, and Emerging Treatments.

Authors:  Erik A Imel; Andrew Biggin; Aaron Schindeler; Craig F Munns
Journal:  JBMR Plus       Date:  2019-05-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.